Overview

Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Status:
Recruiting
Trial end date:
2023-10-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of vedolizumab intravenous IV as induction and maintenance treatment in Chinese participants with moderately to severely active ulcerative colitis (UC).
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Vedolizumab